Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:03 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients
NCT02177682 · Novartis Pharmaceuticals · PHASE1 · terminated · last registry update 2021-08-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Company decision” | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against AKT2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-04-27Phase 3 first posted: AstraZeneca, capivasertib + docetaxel (NCT05348577)
- 2022-03-02Results posted on the registry: National Cancer Institute (NCI), Trametinib + Uprosertib (NCT01989598)
- 2022-02-17Results posted on the registry: Genentech, Inc., 5-Fluorouracil + Ipatasertib (NCT01896531)
- 2022-01-12Results posted on the registry: M.D. Anderson Cancer Center, Erlotinib + AZD6244 (NCT01248247)
- 2021-10-25Also stopped (withdrawn): Washington University School of Medicine, Diagnostic Imaging ( 6α-[18F]fluoro-17β-estradiol (FES)) (NCT01714128)
- 2021-08-10Results posted on the registry: National Cancer Institute (NCI), Capivasertib (NCT04439123)
- 2021-04-28Phase 3 first posted: AstraZeneca, Capivasertib + Fulvestrant (NCT04862663)
- 2021-04-20Phase 3 first posted: Laekna Limited, Afuresertib + Afuresertib/placebo (NCT04851613)
- 2021-01-11Results posted on the registry: Genentech, Inc., Ipatasertib + Paclitaxel (NCT02162719)
- 2020-12-02Phase 3 first posted: Canadian Cancer Trials Group, Ipatasertib + Fulvestrant (NCT04650581)
- 2020-10-14Results posted on the registry: National Cancer Institute (NCI), Dabrafenib Mesylate + Trametinib Dimethyl Sulfoxide (NCT01902173)
- 2020-10-06Also stopped (withdrawn): Icahn School of Medicine at Mount Sinai, Ipatasertib + Paclitaxel (NCT04561817)
- 2020-09-30Also stopped (terminated): ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), ARQ 092 + carboplatin + paclitaxel (Closed) + ARQ 092 + paclitaxel (Closed) (NCT02476955)
- 2020-09-24Also stopped (terminated): Prescient Therapeutics, Ltd., Triciribine + Carboplatin (NCT01690468)
- 2020-09-24Also stopped (terminated): Prescient Therapeutics, Ltd., Cyclophosphamide + Doxorubicin Hydrochloride (NCT01697293)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision